Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Rare Disease Genome Editing Market Size And Revenue Outlook Through 2030
The market size for rare disease genome editing has experienced swift expansion recently. This market is projected to expand from $1.29 billion in 2025 to $1.51 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.8%. Historically, this growth can be ascribed to several factors including progress in gene editing technologies, a rise in the identification of rare genetic mutations, increased funding for genomic research, initial successes in gene therapy trials, and expanding academic research endeavors.
The rare disease genome editing market is anticipated to experience substantial growth in the coming years. It is forecast to expand to $2.88 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 17.5%. This growth throughout the forecast period can be attributed to several factors, including increased investment in curative rare disease therapies, a rising acceptance of precision medicine approaches, the expansion of clinical genome editing trials, growing regulatory support for orphan drugs, and increased collaboration between biotech companies and healthcare providers. Notable trends during this period are expected to encompass the increasing adoption of CRISPR-based therapeutics, a rising focus on gene editing for monogenic disorders, the growing utilization of personalized genome editing approaches, the expansion of advanced editing platforms, and enhanced integration of genomic data analytics.
Get A Free Sample Report With In-Depth Market Insights:
Rare Disease Genome Editing Market Growth Catalysts And Demand Drivers
An escalating emphasis on precision medicine is anticipated to fuel the expansion of the rare disease genome editing market in the future. This tailored healthcare methodology leverages an individual’s genetic makeup, environmental factors, and lifestyle choices to deliver more precise and efficacious therapies. The heightened interest in precision medicine stems from progress in genomic sequencing and the identification of biomarkers, which facilitate accurate detection and the development of targeted treatments. The rare disease genome editing market plays a crucial role in advancing precision medicine by allowing for the specific correction of genetic mutations, thereby enhancing the personalization and efficacy of treatments. This technology improves healthcare by tackling the fundamental causes of rare conditions, leading to better patient results and a decreased dependence on managing symptoms alone. Illustratively, in March 2024, Novotech, an Australia-based biotechnology firm, reported that in 2023, out of 217 FDA-approved oncology treatments, 43% were precision oncology treatments, with 78 of these integrating DNA or NGS-detectable biomarkers. Consequently, the growing concentration on precision medicine is a key impetus for the expansion of the rare disease genome editing market.
Rare Disease Genome Editing Market Segment Outlook: Which Categories Are Growing Fastest?
The rare disease genome editing market covered in this report is segmented –
1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies
2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders
3) By Application: Therapeutics, Research
4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals
Subsegments:
1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing
2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases
3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)
4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases
Rare Disease Genome Editing Market Trends Shaping Long-Term Demand
Leading companies within the rare disease genome editing market are prioritizing the development of advanced therapeutic platforms, specifically CRISPR-based gene editing systems. This focus aims to enhance treatment precision, improve therapeutic outcomes, and address genetic diseases previously considered incurable. CRISPR-based gene editing systems represent innovative technologies enabling precise modifications to the genome, thereby allowing for the correction of genetic defects or the introduction of therapeutic genes into cells. For example, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and obtained conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is indicated for patients aged 12 and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises, or those with transfusion-dependent beta thalassemia (TDT). CASGEVY functions by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, which in turn reduces or eliminates disease symptoms and presents a potential functional cure for these conditions.
Rare Disease Genome Editing Market Leading Companies And Competitive Benchmarking
Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc
View The Full Rare Disease Genome Editing Market Report:
Rare Disease Genome Editing Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model